IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
about
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsNK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell EngraftmentThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesNatural killer cell biology: an update and future directionsKiller immunoglobulin-like receptors and tumor immunityThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentDevelopment of Novel Immunotherapies for Multiple MyelomaUnderstanding of molecular mechanisms in natural killer cell therapyUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsKiller-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women.A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.Pharmacokinetics and tissue disposition of lenalidomide in mice.The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaA phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myelomaThe favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cellsCombination immune therapies to enhance anti-tumor responses by NK cells.Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.The role of natural killer cells in immunity against multiple myeloma.Combining immunotherapy and targeted therapies in cancer treatment.Targeting natural killer cells and natural killer T cells in cancer.Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapyMonoclonal antibody-based immunotherapy for multiple myeloma.The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Immunotherapeutic approaches to treat multiple myelomaImmunotherapy for multiple myeloma.Clinical utility of natural killer cells in cancer therapy and transplantation.Role of NK cells in immunotherapy and virotherapy of solid tumors.Targeting B-cell maturation antigen in multiple myeloma.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.Adoptive Cell Therapy in Multiple Myeloma.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Dendritic cell-derived exosomes for cancer therapy.Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2AImmunosenescence: limitations of natural killer cell-based cancer immunotherapy.CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
P2860
Q26751011-0ADC5776-68FE-46C5-9B67-0C50EB99EB1CQ26765845-ED2D082E-49DD-4827-A6D7-7C14CE0A60B0Q26774678-01DD1037-32AF-4188-A01F-F9BD3B806042Q26799104-80372538-E14E-434F-9DC1-BDE38A6DFE07Q26830512-35B1CD19-D02C-4B2D-A50F-448260863DA8Q27005792-290C289E-9195-4691-A4FF-20659102B615Q27022789-D2604BF1-5B6B-4D37-B903-FE4AF852881BQ28066890-A74AAB66-0765-4E44-8F48-88B0222501A9Q28086976-B82176A6-B89B-4BEB-9C0B-9B6887ADCFB4Q34253548-B1C6EB07-C6C1-4714-B3E1-038FC589B1A6Q34688644-08CDB623-CAF2-45E0-8F9A-B38EC4A178B7Q35157421-E72CBA2B-C713-4688-8202-CF13416C379FQ35904239-A668FE22-E907-4FCE-9972-BD2CB5CD4026Q36070261-0F24F331-36C2-4E8F-B59C-456BA18876E0Q36331493-F2D42311-A44E-4A9D-9773-705F411C8786Q36414249-8036C0B8-34B7-4011-A9F7-4B5A3A5A4661Q36425427-49E54BF7-2495-440A-B4D5-0803BD4FFD4AQ36691438-CC65753E-2436-4900-84DD-10C69580C0F3Q37216218-B020E76E-DFDD-4746-BAAC-1DFA516D5F13Q37408550-3E39D6AF-9AF2-4765-B189-BE350434699BQ37535232-AD26460F-1919-400C-93CA-C23E6D4D569DQ37994234-58E370CB-DF72-4326-BFA8-8FE248364EDDQ37995939-DCA938E1-8F0A-45B9-AE5F-990D1A6A6D00Q37995950-F9AEF11E-3C78-4EAE-BC6A-CB76F0DDA5ADQ38019320-B457DC3C-CDD9-42BE-9229-59BDEF915E56Q38050507-E488871A-F8C5-4076-B691-5463C57C8E98Q38073762-B4D27EC9-2025-4B10-90AC-1BBD8E9EE004Q38074017-4BF4B679-F3C3-4376-94DE-173E03D8D35EQ38171067-17E283C9-2CF2-4753-A01D-8CA52B483F91Q38177879-0483AE20-7EB7-4CDC-BA37-C143A341F554Q38195120-340CACCF-852B-4AEE-B0AC-65256A854F6BQ38575116-16AB510E-ED45-48A8-94EF-FE884F49204AQ38586922-EBD3BD4C-16B2-4EF3-A27F-2DC6DEE7ACE1Q38599353-1D206627-4C4C-4CA1-9218-2199C25C9D30Q38635138-77CDB183-6C7C-459E-B48D-BCAFD155ED09Q38737970-5D5315B7-C5BB-4869-86D1-415ECABFFD51Q38795623-B70902A0-A6FF-4F03-B4E7-BE388D58B180Q38881386-62DE9E35-F3F3-4CE5-B22E-2FF4A0C89D81Q38928938-848620A9-553C-4D64-B8A7-8BDE011A8AF4Q38945158-32C567BE-E9C3-4ECD-B947-4F8BD19B8390
P2860
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
IPH2101, a novel anti-inhibito ...... ersus multiple myeloma effect.
@en
IPH2101, a novel anti-inhibito ...... ersus multiple myeloma effect.
@nl
type
label
IPH2101, a novel anti-inhibito ...... ersus multiple myeloma effect.
@en
IPH2101, a novel anti-inhibito ...... ersus multiple myeloma effect.
@nl
prefLabel
IPH2101, a novel anti-inhibito ...... ersus multiple myeloma effect.
@en
IPH2101, a novel anti-inhibito ...... ersus multiple myeloma effect.
@nl
P2093
P2860
P1433
P1476
IPH2101, a novel anti-inhibito ...... ersus multiple myeloma effect.
@en
P2093
Courtney E Bakan
Cécile Bonnafous
David Clever
Don M Benson
Francois Romagne
Jianying Zhang
Jing Liang
Mathieu Bléry
Michael A Caligiuri
Pascale Andre
P2860
P304
P356
10.1182/BLOOD-2011-06-360255
P407
P577
2011-10-26T00:00:00Z